Goldman Sachs Group Inc Cue Biopharma, Inc. Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 14,401 shares of CUE stock, worth $9,792. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,401
Previous 14,401 -0.0%
Holding current value
$9,792
Previous $13,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025
SELL
$0.91 - $1.75 $18,312 - $35,217
-20,124 Reduced 58.29%
14,401 $13,000
Q4 2024

Feb 11, 2025
BUY
$0.71 - $1.88 $11,333 - $30,008
15,962 Added 85.99%
34,525 $35,000
Q3 2024

Nov 14, 2024
SELL
$0.45 - $1.08 $111,514 - $267,634
-247,810 Reduced 93.03%
18,563 $14,000
Q2 2024

Aug 13, 2024
BUY
$1.24 - $2.18 $273,711 - $481,202
220,735 Added 483.66%
266,373 $330,000
Q1 2024

May 15, 2024
SELL
$1.77 - $3.09 $22,454 - $39,199
-12,686 Reduced 21.75%
45,638 $86,000
Q4 2023

Feb 13, 2024
BUY
$1.72 - $3.1 $67,442 - $121,554
39,211 Added 205.15%
58,324 $153,000
Q3 2023

May 14, 2024
SELL
$2.23 - $4.69 $87,440 - $183,899
-39,211 Reduced 67.23%
19,113 $43,000
Q3 2023

Nov 14, 2023
BUY
$2.23 - $4.69 $3,358 - $7,063
1,506 Added 8.55%
19,113 $43,000
Q2 2023

May 14, 2024
BUY
$3.11 - $4.91 $11,454 - $18,083
3,683 Added 26.45%
17,607 $64,000
Q2 2023

Aug 14, 2023
BUY
$3.11 - $4.91 $11,454 - $18,083
3,683 Added 26.45%
17,607 $64,000
Q1 2023

May 14, 2024
SELL
$2.41 - $3.74 $392 - $609
-163 Reduced 1.16%
13,924 $49,000
Q1 2023

May 11, 2023
SELL
$2.41 - $3.74 $392 - $609
-163 Reduced 1.16%
13,924 $49,000
Q4 2022

May 14, 2024
BUY
$2.39 - $3.95 $262 - $434
110 Added 0.79%
14,087 $40,000
Q4 2022

Feb 13, 2023
BUY
$2.39 - $3.95 $262 - $434
110 Added 0.79%
14,087 $40,000
Q3 2022

May 14, 2024
SELL
$2.23 - $3.37 $303,788 - $459,088
-136,228 Reduced 90.69%
13,977 $31,000
Q3 2022

Nov 10, 2022
SELL
$2.23 - $3.37 $303,788 - $459,088
-136,228 Reduced 90.69%
13,977 $0
Q2 2022

May 14, 2024
BUY
$2.49 - $5.92 $228,783 - $543,935
91,881 Added 157.54%
150,205 $374,000
Q2 2022

Aug 15, 2022
SELL
$2.49 - $5.92 $876 - $2,083
-352 Reduced 0.23%
150,205 $374,000
Q1 2022

May 16, 2022
SELL
$4.41 - $12.28 $8,229 - $22,914
-1,866 Reduced 1.22%
150,557 $735,000
Q4 2021

Feb 14, 2022
SELL
$10.86 - $17.85 $890,541 - $1.46 Million
-82,002 Reduced 34.98%
152,423 $1.72 Million
Q3 2021

Nov 10, 2021
BUY
$10.06 - $15.3 $2.36 Million - $3.59 Million
234,425 New
234,425 $3.42 Million

Others Institutions Holding CUE

# of Institutions
52
Shares Held
11.5M
Call Options Held
10.1K
Put Options Held
1.4K
View Full List

About Cue Biopharma, Inc.

CUE Quotes by TradingView
  • Ticker CUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,381,700
  • Market Cap $24.1M
  • Description
  • Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...
More about CUE
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email